Tirabrutinib maintenance versus placebo in patients with primary central nervous system lymphoma in complete remission: a randomized phase II study (JCOG2104)

agane Motoo0 个研究点目标入组 92 人开始时间: 2023年8月3日最近更新: 2023年10月17日

试验速览

阶段: 2 期
状态: 招募中
发起方
入组人数: 92

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 18age old 至 ot applicable（—）

入选标准

•1) Histopathological diagnosis of B cell lymphoma.
•2) Newly-diagnosed PCNSL confined to the cerebrum, cerebellum and brainstem. Patients with or without interocular lymphoma are eligible.
•3) Negative cerebrospinal fluid (CSF) cytology, or no evidence of leptomeningeal lymphomatosis in contrast-enhanced magnetic resonance imaging (MRI) of the brain and the whole spinal cord.
•4) No evidence of systemic lymphoma before induction chemotherapy, confirmed by contrast-enhanced CT including the neck, chest, abdomen, pelvic cavity and groin, or whole-body positron-emission tomography (PET) and CT.
•5) Patients with a single lesion, or multiple lesions, are eligible.
•6) Patients 18 years old or older at the time of registration.
•7) Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1, 2.
•8) Have completed either of the following methotrexate (MTX)-based chemotherapy
•i) R-MPV (rituximab, MTX, procarbazine and vincristine)
•ii) MPV (MTX, procarbazine and vincristine)
•iii) R-MP (rituximab, MTX and procarbazine)
•iv) MP (MTX and procarbazine)
•v) R-M (rituximab and MTX)
•vi) MTX monotherapy
•9) Complete response (CR) or complete response unconfirmed (CRu) based on the International PCNSL Collaborative Group (IPCG) criteria.
•10) Within 60 days from the last dose of induction or consolidation chemotherapy.
•11) No treatment history of radiotherapy for PCNSL.
•12) Refused to receive consolidation radiotherapy.
•13) No treatment history of chemotherapy or radiotherapy, except for stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT) for non-cancer diseases (such as arteriovenous malformations).
•14) Adequate organ function.
•i) Neutrophil count >=1,000/mm3
•ii) Hemoglobin >= 8.0 g/dl
•iii) Platelet count >= 75,000/mm3
•iv) AST <=120 U/L
•v) ALT <= 120 U/L
•vi) Total Bilirubin <= 2.25 mg/dl
•vii) Creatinine <= 1.5 mg/dL
•15) Written informed consent.

排除标准

•1) Synchronous or metachronous malignancies.
•2) Infections requiring systemic treatment at the time of registration.
•3) Body temperature >=38 degree celsius at the time of registration.
•4) Serious lung disorders, such as interstitial pneumonia, obstructive lung disease, hypersensitive pneumonitis, symptomatic bronchospasm) at the time of registration.
•5) History or presence of aspergillus pneumonitis or pneumocystis pneumonia.
•6) History of serious drug allergy or serious anaphylaxis.
•7) Heart failure (>= III in New York Heart Association functional classification), unstable angina pectoris, or history of myocardial infarction within the preceding 180 days prior to registration.
•8) Treated by anticoagulants at the time of registration.
•9) Treated by antiplatelets at the time of registration.
•10) Uncontrolled autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP).
•11) Immune deficiency, such as acquired immunodeficiency syndrome (AIDS), X-linked agammaglobulinemia, chronic granulomatous disease, Wiskott-Aldrich syndrome, or any other iatrogenic immunosuppressive conditions.
•12) Post organ transplant immunosuppression.
•13) Prednisone use of >10 mg/day for condition other than intracranial tumor, or regular use of immunosuppressants.
•14) Uncontrolled diabetes mellitus.
•15) Treated either by CYP3A4 inhibitors, CYP3A4 inducers, or P-gp inducers within 14 days prior to registration.
•16) Gadolinium allergy.
•17) Positive HIV antibody.
•18) Positive HBs antigen.
•19) Positive HBs antibody or HBc antibody, and HBV-DNA positive.
•20) Positive HCV antibody.
•21) Unable to take oral medicine,
•22) Females during pregnancy, or within 28 days postpartum, or during lactation. Males who wish childbearing of his partner.
•23) Prior history of treatment by BTK inhibitors.
•24) Severe psychiatric disorders.

研究者

发起方

agane Motoo

相似试验

进行中（未招募）

1 期

Trabectedin maintenance post 1st-line in STSMetastatic soft tissue sarcomaMedDRA version: 20.0Level: PTClassification code 10075333Term: Soft tissue sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2016-003535-38-ITEORTC AISBL/IVZW90

进行中（未招募）

1 期

Trabectedin maintenance post 1st-line in STS

EUCTR2016-003535-38-PLEuropean Organisation for Research and Treatment of Cancer90

撤回

3 期

Maintenance therapy with trabectedin versus observation after first line treatment with doxorubicin of patients with advanced or metastatic soft tissue sarcoma

NL-OMON45391European Organisation for Research in Treatment of Cancer (EORTC)8

进行中（未招募）

1 期

EUCTR2016-003535-38-NLEuropean Organisation for Research and Treatment of Cancer (EORTC)90

进行中（未招募）

1 期

EUCTR2016-003535-38-FREuropean Organisation for Research and Treatment of Cancer90